FDA Approves YUSIMRY — Coherus BioSciences Inc
On December 17, 2021, the FDA approved Coherus BioSciences' commercial footprint by granting accelerated approval for YUSIMRY (adalimumab-aqvH), the rapidly-subcutaneous formulation of Humira. This launch is expected to provide a cost-effective alternative to Humira by mitigating the financial advantages of AbbVie’s offset agreements, thereby significantly impacting the competitive landscape for biologics in autoimmune markets.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed